Demant AS
DEMANT: XCSE (DNK)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| Sp@ | LOCK|nYRf | LOCK|vLr<rh% |
Demant Earnings: Oticon Zeal Momentum Drives Guidance Upgrade; Shares Fairly Valued
Demant reported second-quarter sales growth in constant currencies of 19%, split between 9% organic and 10% inorganic, the latter stemming from the Kind acquisition. The adjusted EBIT margin expanded to 16.5% from 16.4% over the first half of 2026. Management raised its full-year guidance.
